NYSE: NMRNomura Holdings Inc Stock
$6.55-0.02 (-0.3%)
Updated Jul 2, 2025
NMR Price
$6.55
Fair Value Price
N/A
Market Cap
$19.36B
52 Week Low
$4.66
52 Week High
$6.99
P/E
8.23x
P/B
0.81x
P/S
1.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.07B
Earnings
$2.28B
Gross Margin
90.6%
Operating Margin
24.59%
Profit Margin
18%
Debt to Equity
15.33
Operating Cash Flow
-$5B
Beta
0.79
Next Earnings
Jul 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NMR Overview
Nomura Holdings, Inc. offers securities, investment and other financial sevices to individuals, corporations, financial institutions, and governments. Its Sales segment provides investment consultation services to individual clients in Japan. The Asset Management segment offers development and management of investment trusts and investment advisory services. The Wholesale segment sells and trade bonds, equity securities, derivatives and foreign exchange. Nomura Holdings was incorporated in 1925 and is headquartered in Tokyo, Japan.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NMR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Capital Market
Industry Rating
F
NMR
Ranked#17 of 57
Ranked#17 of 57
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $5.54 | A | |
| $10.76 | A | |
| $4.85 | B |
Be the first to know about important NMR news, forecast changes, insider trades & much more!
NMR News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NMR scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NMR is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NMR is good value based on its earnings relative to its share price (8.23x), compared to the US market average (31.27x)
P/E vs Market Valuation
NMR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more NMR due diligence checks available for Premium users.
Valuation
NMR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
8.23x
Industry
22.57x
Market
31.27x
NMR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NMR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
NMR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.81x
Industry
2.57x
NMR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NMR's financial health
Profit margin
Revenue
$12.7B
Net Income
$2.3B
Profit Margin
18%
NMR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$380.5B
Liabilities
$356.5B
Debt to equity
15.33
NMR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NMR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5B
Investing
-$5.7B
Financing
$11.3B
NMR vs Capital Market Stocks
Nomura Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.